Targeted alpha therapy in vivo: Direct evidence for single cancer cell kill using 149Tb-rituximab

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 4, 2004, Pages 547-554

  Beyer, G J ^a   Miederer, M ^b   Vranjes Duric S ^c   Comor J J ^c   Kunzi G ^d   Hartley, O ^d   Senekowitsch Schmidtke, R ^e   Soloviev, D ^a   Buchegger, F ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alpha particle emitting radionuclides; Leukaemia; Radio immunotherapy; Rituximab; Terbium 149

Indexed keywords

ANTIBODY CONJUGATE; CD20 ANTIBODY; RADIOISOTOPE; RITUXIMAB; TERBIUM; TERBIUM 149; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE TISSUE; CANCER CELL; CELL KILLING; COMBINED IMMUNODEFICIENCY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DAUDI CELL; GENE THERAPY; GRAFT SURVIVAL; IN VIVO STUDY; LIVER; LYMPHOMA; MOUSE; NONHUMAN; RADIOIMMUNOTHERAPY; SPLEEN CELL;

EID: 1842714861     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1413-9     Document Type: Article

References (28)

1. Hall EJ. Radiobiology for the radiologist. 4th edn. Philadelphia: Lippincott, 1994.
2. Maecklis RM, Lin JY, Beresford B, Achter RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: inducing of apoptosis. Radiat Res 1992; 130:220-226.
3. 225Ac-radiopharmaceuticals. Appl Rad Isot 2002; 57:841-847.
4. Allen BJ, Blagojevic N. Alpha and beta emitting radiolanthanides in targeted cancer therapy: the potential role for terbium-149. Nucl Med Commun 1996; 17:40-47.
5. Zalutsky MR, Vaidyanathan G. Astatine-211 labeled radiotherapeuticals: an emerging approach to targeted alpha particle therapy. Current Pharm. Design 2000; 6:1433-1455.
6. Huber R, Seidl C, Schmid E, Seidenschwang S, Becker K-F, Schuhmacher C, Apostolidis C, Nikula T, Kremmer E, Schwaiger M, Senekowitsch-Schmidtke. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody. Clin Cancer Res 2003; 9:3922-3928.
7. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangmd ÅM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted α-particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233-1239.
8. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA. Radioimmunotherapy with alpha-emitting radionuclides. Eur J Nucl Med 1998; 25:1341-1351.
9. Allen BJ, Goozee G, Imam S, Sarkar S, Leigh J, Beyer G-J. Targeted cancer therapy: The potential role of terbium-149. 6th International Conference on Radiopharmaceutical Dosimetry, Gatlington, Tenn. (USA), May 7-10, 1996, CERN-PPE/96-127, 1996
10. Charlton DE, Utteridge TD, Allen BJ. Theoretical treatment of human hemopoietic stem cell survival following irradiation by alpha particles. Int J Radiat Biol 1998; 74:111-118.
11. Allen BJ. Can alpha immunotherapy succeed where other modalities have failed? Nucl Med Commun 1999; 20:205-207.
12. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002; 43:267-272.
13. Miederer M, Seidl C, Beyer G-J, Charlton DE, Vranječ-Durić SD, Čomor JJ, Huber R, Nikula T, Apostolidis C, Schuhmacher C, Becker K-F, Senekowitsch-Schmidtke R. Comparison of the radiotoxicity of two alpha emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein. Radiat Res 2002; 159:612-620.
14. Vranječ SD, Miederer M, Čomor JJ, Soloviev D, Beyer G-J and the ISOLDE collaboration. Labeling of monoclonal antibodies with 149-Tb for targeted alpha therapy. J Lab Comp Radiopharm 2001; 44:718-720.
15. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int J Cancer 1990; 45:481-485.
16. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. Tumor therapy with targeted atomic nanogenerators. Science 2001; 294:1537-1540.
17. Firestone RB. Table of isotopes, 8th edn. New York: Wiley-Interscience, 1996.
18. Kugler E. The ISOLDE facility. Hyperfine Interactions 2000; 129:23-42.
19. Beyer G-J, Čomor JJ, Daković M, Soloviev D, Tamburella C, Hagebø E, Allan B, Dmitriev SN, Zaitseva NG, Starodub GY, Molokanova LG, Vranječ SD, Miederer M, and the ISOLDE Collaboration. Production routes of the alpha emitting 149-Tb for medical application. Radiochim Acta 2002; 90:247-252.
20. Beyer G-J, Offord RE, Künzi G, Jones RML, Ravn U, Aleksandrova Y, Werlen RC, Mäcke H, Lindroos M, Jahn S, Tengblad O, and the ISOLDE Collaboration. Biokinetics of monoclonal antibodies labeled with radio-lanthanides and 225-Ac in xenografted nude mice. J Label Compd Radiopharm 1995; 37:229-530.
21. Beyer G-J, Münze R, Fromm WD, Franke WG, Henke E, Khalkin VA, Lebedev NA. Spallation produced 167-Tm for medical application. In: Medical radionuclide imaging 1980, vol 1. Vienna: IAEA; 1981:587 (IAEA-SM-247/60).
22. 225Ac in tumor bearing mice. Nucl Med Biol 1997; 24:367-372.
23. 225Ac and radiolanthanides as citrate complexes. Isotopenpraxis 1990; 26:111-114.
24. Beyer G-J, Herrmann E, Khalkin VA. Chemical effects related to different radioactive decay processes of cerium isotopes chelated with different polyaminocarbonic acids. Dubna: JINR P 12-7758, 1974.
25. Beyer G-J, Herrmann E. Chemical effects of nuclear transformations in lanthanide chelate complexes. In: Proceedings of the COST Chemistry Action D18, Mid Term Evaluation Workshop on Lanthanide Chemistry for Diagnosis and Therapy, Heidelberg (Germany), July 22-25, 2002, p 26.
26. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37:538-546.
27. Breeman WAP, DeJong M, Krenning EP. Labeling of DOTA-peptides at high specific activities. ICFE'5, Geneva, Switzerland, August 24-29, 2003, CO4-SL8, abstract book p 197.
28. Beyer G-J, Ruth TJ. The role of electromagnetic separators in the production of radiotracers for bio-medical research and nuclear medical applications. NIM B 2003; 204:694-700.